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Abstract
AIM: To investigate the ability of a Prunella vulgaris 
(P. vulgaris ) ethanolic extract to attenuate spontaneous 
typhlocolitis in mdr1a-/- mice. 
METHODS: Vehicle (5% ethanol) or P. vulgaris  ethano-
lic extract (2.4 mg/d) were administered daily by oral 
gavage to mdr1a-/- or wild type FVBWT mice from 6 wk of 
age up to 20 wk of age. Clinical signs of disease were 
noted by monitoring weight loss. Mice experiencing 
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weight loss in excess of 15% were removed from the 
study. At the time mice were removed from the study, 
blood and colon tissue were collected for analyses that 
included histological evaluation of lesions, inflammatory 
cytokine levels, and myeloperoxidase activity. 
RESULTS: Administration of P. vulgaris  extracts to 
mdr1a-/- mice delayed onset of colitis and reduced 
severity of mucosal inflammation when compared to 
vehicle-treated mdr1a-/- mice. Oral administration of the 
P. vulgaris  extract resulted in reduced (P  < 0.05) serum 
levels of IL-10 (4.6 ± 2 vs  19.4 ± 4), CXCL9 (1319.0 
± 277 vs  3901.0 ± 858), and TNFα (9.9 ± 3 vs  14.8 ± 
1) as well as reduced gene expression by more than 
two-fold for Ccl2, Ccl20, Cxcl1, Cxcl9, IL-1α, Mmp10, 
VCAM-1, ICAM, IL-2,  and TNFα  in the colonic mucosa 
of mdr1a-/- mice compared to vehicle-treated mdr1a-/- 
mice. Histologically, several microscopic parameters 
were reduced (P  < 0.05) in P. vulgaris -treated mdr1a-/- 
mice, as was myeloperoxidase activity in the colon 
(2.49 ± 0.16 vs  3.36 ± 0.06, P  < 0.05). The numbers 
of CD4+ T cells (2031.9 ± 412.1 vs  5054.5 ± 809.5) 
and germinal center B cells (2749.6 ± 473.7 vs  4934.0 
± 645.9) observed in the cecal tonsils of P. vulgaris -
treated mdr1a-/- were significantly reduced (P  < 0.05) 
from vehicle-treated mdr1a-/- mice. Vehicle-treated 
mdr1a-/- mice were found to produce serum antibodies 
to antigens derived from members of the intestinal 
microbiota, indicative of severe colitis and a loss of 
adaptive tolerance to the members of the microbiota. 
These serum antibodies were greatly reduced or absent 
in P. vulgaris -treated mdr1a-/- mice. 
CONCLUSION: The anti-inflammatory activity of P. 
vulgaris  ethanolic extract effectively attenuated the 
severity of intestinal inflammation in mdr1a-/- mice.
Key words: Prunella vulgaris ; Spontaneous colitis; 
Inflammatory bowel disease; Mdr1a; Botanical extract; 
Mucosal inflammation; Nutraceutical
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Extracts of Prunella vulgaris (P. vulgaris ) 
contain multiple anti-inflammatory phenolics and 
flavonoids and we report that oral administration of an 
ethanolic extract of P. vulgaris  ameliorated the severity 
of spontaneous colitis in 20 wk old mdr1a-/- mice. 
Because these mice are genetically prone to develop 
colitis by 10 wk of age, daily oral treatments were 
initiated at 6 wk of age. This treatment regimen resulted 
in the inhibition of multiple parameters of inflammation 
that collectively contributed to ameliorate the severity of 
mucosal inflammation suggesting that botanical extracts 
may be used as effective complementary intervention 
strategies for the treatment of colitis. 
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INTRODUCTION
The intestinal epithelium is the interface between the 
host and the lumen of the gastrointestinal tract and 
cooperates with other innate immune mechanisms to 
protect the host from microbial-induced inflammation as 
well as to hinder colonization and invasion by intestinal 
microorganisms. The ability to maintain low levels 
of mucosal inflammation in the gut is believed to be 
important for mucosal homeostasis. However, in the 
context of inflammatory bowel diseases (IBD), such 
as Crohn’s disease (CD) and ulcerative colitis (UC), 
regulation of intestinal inflammation often fails resulting 
in mucosal damage and chronic disease[1]. While 
idiopathic in nature, current hypotheses regarding the 
etiology of IBD point to complex multifactorial causalities, 
which include disruption of the intestinal epithelial barrier, 
dysbiosis of the microbiota, genetic predispositions, 
chronically activated inflammatory immune cells, and 
failed adaptive immune regulatory responses[2,3].
Much IBD research has focused on aberrant adap­
tive immune responses to antigens derived from 
the microbiota. More emphasis is now being placed 
on elucidating the role innate immune cells (e.g., 
neutrophils), cytokines, chemokines, and their related 
transcription factors play in the initiation and/or 
maintenance of epithelial damage as the initial step in 
the onset of IBD[4]. In the absence of effective epithelial 
barrier function, compartmentalization that is meant 
to separate immune cells in the lamina propria from 
the numerous bacterial and food antigens normally 
sequestered in the lumen is lost[5]. A loss of epithelial 
barrier integrity is characteristic of UC and CD, and 
the consequential loss of immunologic tolerance to the 
microbiota initiates a cascade of signaling pathways 
that activate both innate and adaptive immune 
mechanisms[6]. 
The most common therapies used for the treatment 
of IBD are immune suppressive and anti-inflammatory 
drugs and biologicals such as monoclonal antibodies 
(e.g., anti­TNF)[7,8]. Metronidazole and ciprofloxacin have 
also been utilized in several clinical trials related to the 
treatment of UC, CD, and pouchitis with underwhelming 
results[9]. Immunosuppressive therapies include 
monoclonal antibodies against TNF­α, 5­aminosalicylates 
(5­ASA), and steroids[10­12]. For many of these treatments, 
there is the potential for adverse effects that may include 
increased susceptibility to bacterial and viral infections 
and increased risk of cancer. One study showed that IBD 
related hospitalizations at high volume IBD treatment 
centers around the United States increased 6­fold 
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from 1998 to 2004[13]. This data illustrates that despite 
advances in IBD research, current therapies have not 
decreased the frequency of IBD related hospitalizations 
and surgical interventions are still common for severe 
forms of IBD. These facts and the financial burdens 
associated with expensive therapeutic regimens have 
lead patients to explore unconventional means of coping 
with IBD.
A 1998 study showed that up to 51% of surveyed 
IBD patients had used alternative or complementary 
therapies and, in particular, 16% of patients used the 
alternative therapies specifically for their IBD[14]. For 
most complementary therapies (e.g., nutraceuticals), 
many anecdotal claims of health benefits exist with very 
little scientific data to support or negate those claims. 
Prunella vulgaris (P. vulgarisis) commonly used in 
traditional Chinese medicine for wound healing, indiges­
tion, burns and anti­inflammatory therapy. P. vulgaris 
contains several bioactive phenolics, triterpenoids and 
flavonoids[15]. Dietary phenolics such as rosmarinic acid, 
ursolic acid, and caffeic acid are all found in extracts of 
P. vulgaris, and have been shown to possess antioxi­
dant, anti-inflammatory and anti-cancer activities[16­21]. 
Caffeic acid has also been shown to ef)fectively 
attenuate chemically induced experimental colitis 
through upregulation of cytochrome P450 (CYP4B1)[22]. 
Flavonoids, like those found in P. vulgaris, have been 
implicated as potential therapeutics for IBD as well[23]. In 
contrast to its ability to attenuate DSS­induced colitis, the 
flavonoid luteolin was found to attenuate spontaneous 
colitis by inhibiting the activation of NF­κB. Despite this 
promising evidence, there are no published reports 
evaluating the use of P. vulgaris extracts as a treatment 
for IBD. In this context, we have designed this study to 
test the hypothesis that an ethanolic extract of P. vulgaris 
will decrease  gastrointestinal mucosal inflammation and 
thereby ameliorate the severity of spontaneous colitis in 
mdr1a­/­ mice.
MATERIALS AND METHODS
Prunella vulgaris extract preparation
Information about the specific provenance of P. 
vulgaris accession Ames 27664, obtained from Dr. Mark 
Wiederlichner at the USDA­ARS North Central Regional 
Plant Introduction Station (Ames, IA), is available on the 
Germplasm Resources Information Network database 
at http://www.ars­grin.gov/npgs/acc/acc_queries.html. 
Above ground portions of plants from P. vulgaris (Ames 
27664), harvested in 2008 were prepared for storage 
by drying for 8 d at 38 ℃ in a forced­air dryer with 
constant humidity. The dried material was ground with 
a 40­mesh screen and stored at ­20 ℃ under N2 until 
extraction. Weighed plant material was extracted with 
95 ethanol with Soxhlet extractors for 6 h. The extract 
was concentrated by rotary evaporation at < 30 ℃ and 
lyophilized. The residue weight was recorded and the 
residues stored at ­20 ℃ until solubilized in a final 
working solution of 5% ethanol in sterile distilled water 
at a final plant extract concentration of 12 mg/mL. The 
working P. vulgaris extract was divided into 2 mL aliquots 
and stored at ­20 ℃ until use. P. vulgaris extracts from 
North Central Regional Plant Introduction Station were 
screened for endotoxin by using the Limulus Amebocyte 
Lysate Test (BioWhittaker, Inc., Walkersville, MD) 
according to manufacturers’ specifications, and there 
was no detectable endotoxin present in the extract 
(data not shown). Extracts were tested for antimicrobial 
activity in vitro with no activity demonstrated.
Animals 
Prior to the initiation of any work being performed, 
all animal related experiments were approved by the 
Institutional Animal Care and Use Committee (IACUC) at 
Iowa State University. Incumbent with IACUC approval, 
methods and procedures were used tomimimize pain 
and/or distress of all animals used in this study. Four 
to five week old male mdr1a­/­ FVB.129P2­Abcb1a 
tm1BorN7 and wild type (WT) FVB.129P2 mice were 
obtained from Taconic Farms, Inc. (Germantown, NY). 
Animals were housed and maintained in the Laboratory 
Animal Resource facility at the College of Veterinary 
Medicine, Iowa State University. Established specific 
pathogen­free husbandry practices were followed, and 
twelve­hour light/dark cycles were applied. Upon arrival 
and throughout the study, mice were fed a defined 
Harlan Teklad AIN93 (M) rodent chow (Madison, WI) to 
control the amount of phytochemicals in their diet.
Experimental design
Three treatment groups of mice where utilized: Mdr1a­/­ 
mice that were orally gavaged with 2.4 mg/d P. vulgaris 
extract in a 200 µL volume (prepared as described 
above) and mdr1a­/­ and FVBWT mice were orally 
gavaged with 5% ethanol vehicle alone; there were 4 to 
10 mice/group per experiment. Gavage was performed 
using a 20 gauge feeding needle once daily beginning 
at 6 wk of age until the mice reached 20 wk of age or 
were removed from the study because of severe clinical 
wasting and/or weight loss exceeding 15% of their peak 
body weight in order to minimize pain and discomfort. 
At necropsy, mice were euthanized by CO2 asphyxiation. 
Following euthanasia, blood was collected by cardiac 
puncture and separate sections of each cecum and 
proximal colon were excised, washed, and stored for 
further histological, myeloperoxidase (MPO) enzymatic 
and real­time PCR analysis. Serum was analyzed by 
multiplex assay to measure cytokine and chemokine 
levels as well as western blot analysis for antibody 
reactivity to antigens derived from selected members 
of the microbiota. Cecal tonsils were also collected for 
flow cytometric analysis of T and B cell populations. 
All results are representative of two independent 
experiments.
Macroscopic typhlocolitis assessment
Following euthanization, the colon and cecum were 
excised, photographed, measured and scored for 
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severity of macroscopic lesions. Gross typhlocolitic 
lesions were scored using a 9­point additive scale: A 
score of zero being a healthy animal and a score of 9 
being a maximally diseased animal. Score parameters 
evaluated included: (1) cecal atrophy; (2) enlarged 
cecal tonsil or other enlarged lymphoid aggregates; 
(3) emptying of cecal contents; (4) abnormally watery 
or mucoid intraluminal cecal and/or colonic contents; 
(5) bloody cecal contents; (6) bloody colonic contents; 
(7) visible thickening and rigidity of the cecum; (8) 
presence of visible thickening and rigidity of the colon; 
and (9) absence of formed fecal pellets in the colon. In 
accordance with approved IACUC protocol, mice that 
developed severe colitis prior to 20 wk of age were 
removed from study when they lost ≥ 15% of their 
maximal body weight. Mice were also removed from the 
study within 5 d of the onset of persistent clinical signs 
of disease as characterized by bloody stools, diarrhea, 
ruffled fur, and hunched gate.
Histopathological assessment
Sections of excised cecum and proximal colon were 
placed in 10% buffered formalin overnight, paraffin 
embedded, sectioned, and routinely stained with 
hematoxylin and eosin. Stained colonic and cecal 
sections were scored by a board­certified veterinary 
pathologist, Dr. Jesse Hostetter of Iowa State University 
(Ames, IA), blinded to the treatments as previously 
described[24,25]. Microscopic mucosal lesion scores were 
assessed by five parameters, with each parameter 
scored on a scale of 0­5 (5 = maximum severity). 
Score parameters include: (1) ulceration of the mucosa; 
extent of inflammatory cell infiltrate; (2) mucosal 
edema characterized by the extent of lymphatic and 
vascular distortion and expansion of the mucosa/
submucosa by clear space; (3) stromal collapse and 
necrosis of the glands; and (4) glandular hyperplasia 
characterized by the crowding and immaturity of 
enterocytes along the gland and gland dilation. In 
addition to score, mucosal height was determined and 
recorded as a ratio of gland height to gland width, and 
the specific inflammatory cell populations, if present, 
were recorded. Score parameters were considered 
individually and as an additive histopathological score 
with mucosal height included in the additive score.
Myeloperoxidase assay
MPO activity was assessed as a measure of neutrophil/
granulocyte accumulation in proximal colonic tissues. 
The MPO assay was performed as previously described 
with several modifications[22]. Proximal colon sections 
collected at necropsy were gently flushed with PBS to 
remove luminal contents and stored in 1 mL of freshly 
prepared PBS supplemented with the protease inhibitor 
phenylmethanesulfonyl fluoride (PMSF) at 0.1 mmol/L 
and 15% dimethylsulphoxide (DMSO) at ­20 ℃ for no 
more than 7 d prior to assay. Samples used as positive 
controls for MPO activity were prepared fresh the day the 
assay from peripheral blood. One FVBWT mouse, not on 
study, was euthanized by CO2 asphyxiation, and 500 µL 
to 1 mL of blood was immediately collected by cardiac 
puncture with a heparinized needle (heparin at 5000 
USP heparin units/0.5 mL is drawn into the needle and 
syringe and then expelled to coat the inside of the needle 
with heparin). The heparinized blood was centrifuged at 
250 x g for 10 min, the supernatant discarded and the 
red blood cells (RBC) lysed. In brief, 1 mL of ACK lysis 
buffer (8042 mg/L ammonium chloride, 1001 mg/L 
potassium bicarbonate, 3.722 mg/L ethylene diamine 
tetraacetic acid disodium, pH 7.2) was added to the 
pellet, vortexed gently for 1 min, 1 mL of PBS was added, 
and the mixture was centrifuged for 10 min at 250 x g. 
The lysis was repeated until the pellet was white and the 
supernatant was clear. Following RBC lysis, the pellet was 
resuspended in 1 mL of PBS/PMSF (0.1 mmol/L), cell 
numbers were enumerated using a cell counter (average 
yield of 3 x 106 cells/mL) and the cells were sonicated 
at an amplitude of 5, pulse on for 4 s, pulse off for 1 s, 
for 20 s total. The sonicated tissue samples were then 
centrifuged at 250 x g for 15 min and the supernatant 
stored at 4 ℃ until the tissue samples were prepared. 
Frozen proximal colonic sections were thawed, blotted 
to remove as much excess fluid as possible, trimmed 
to roughly 35 mg and their weights recorded. Tissues 
were then homogenized for 1 min at maximum power 
in 1 mL PBS/PMSF (0.1 mmol/L) and the homogenizer 
probe was washed 5 times with PBS between tissue 
samples. Homogenate cell counts were recorded, and 
each sample was then sonicated as described above. 
The tissue sonicates were then centrifuged at 250 x 
g for 15 min, the supernatant collected and the pellet 
discarded. Each lysate prepared from tissue or peripheral 
blood monocytes (PBMC) was analyzed for total protein 
using a NanoDrop ND­1000 UV­Vis Spectrophotometer 
(NanoDrop Technologies Inc., Wilmington, DE). Individual 
lysates were pipetted into 96-well, flat bottom microtiter 
plates. The PBMC lysates (150 µL/well) were serially 
diluted (10, two­fold dilutions) and analyzed in triplicate 
wells. For each tissue lysate, 150 µL was pipetted into 
separate wells and analyzed in triplicate. To each well, 
50 µL of 0.78 mg/mL 3,3,5,5­tetramethylbenzidine 
dihydrochloride hydrate was added, followed immediately 
by the addition of 50 µL hydrogen peroxide (H2O2) (5 
mmol/L). The reaction was allowed to proceed for 2 
min (wells turned bright blue), followed by the addition 
of 50 µL of sulfuric acid (1 mol/L) to stop the reaction. 
The optical density (OD) was measured at 405 nm 
spectrophotometerically (V­Max, Molecular Devices, 
United States) using SOFTmax PRO 4.0 software. The 
MPO content was determined by comparison to the 
standard curve and MPO activity was expressed as the 
relative units of enzyme activity per gram of wet weight 
of tissue.
Serum cytokine/chemokine quantification
Following euthanasia of mdr1a­/­ and FVBWT mice, blood 
was collected via cardiac puncture. The blood was 
allowed to clot for 24 h at 4 ℃ after which samples were 
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centrifuged at 10000 x g for 10 min. Serum was then 
removed and stored at ­20 ℃ until use. The day of assay, 
serum samples were thawed to room temperature. 
Concentrations of cytokines and chemokines of interest 
were measured using the Millipore (Billerica, MA) mouse 
cytokine­chemokine multiplexed assay kit. Analytes 
screened include: Eotaxin, G­CSF, GM­CSF, IFN­γ, IL­10, 
IL­12 (p40), IL­12 (p70), IL­13, IL­15, IL­17, IL­1α, IL­
1β, IL­2, IL­3, IL­4, IL­5, IL­6, IL­7, IL­9, IP­10, KC, 
LIF, LIX, M­CSF, MCP­1, MIG, MIP­1α, MIP­1β, MIP­2, 
RANTES, TNF­α, and VEGF. The assay was performed 
according to the manufacturer’s instructions. In brief, 
supplied analyte standards (range: 10000 to 3.2 pg/mL), 
quality control standard, and buffer only control samples 
were analyzed in duplicate wells of the supplied 96 well 
plate. Mouse serum samples were diluted 1:1 in supplied 
assay buffer plated for each mouse. Supplied serum 
matrix and supplied assay buffer were added to all wells. 
Supplied pre­conjugated multiplex analyte beads were 
added to each well and the samples were incubated at 
4 ℃ overnight on a plate shaker (Barnstead International 
Titer Plate Shaker, setting 5, Model No. 4625). Supplied 
detection antibody was added to all wells and allowed 
to incubate at room temperature while shaking for 2 
h. Supplied streptavidin­phycoerythrin was incubated 
for 30 min at room temperature while shaking. The 
mean fluorescence intensity (MFI) was measured using 
Luminex platform technology (The FlowMetric System, 
Luminex, Austin, TX). MFIs were subsequently converted 
to concentrations using a 5­parameter logistic or line 
curve-fitting method in MasterPlex QT Software (MiraiBio 
Group, San Francisco, CA).
Flow cytometric analysis of cecal tonsil cell populations
Cecal tonsils from mdr1a­/­ and FVBWT mice were excised, 
placed in complete cell culture medium (10 mL heat­
inactivated FBS, 1 mL penicillin/streptomycin, 1 mL 
glutamine, 0.1 mL 50 mmol/L β­mercaptoethanol, 2.5 
mL 1M Hepes buffer in 85.4 mL DMEM containing 4.5 
g/L glucose and sodium pyruvate), and homogenized 
mechanically on ice. Stainless steel wire strainers (60 
mesh) were used to prepare single cell suspensions and 
remove particulate matter. Cells (5 × 105 cells/tube) 
were washed in FACS buffer, centrifuged at 250 x g 
and incubated in FACS buffer containing 1:100 rat IgG 
and fluorochrome labeled reagents for 15 min on ice. 
Following labeling, cells were washed with FACS buffer, 
centrifuged and fixed in 200 µL of BD stabilizing fixative. 
Cellular preparations from individual mice were label­
ed with the following fluorochrome­labeled reagents: 
Germinal center B cells (PNA+B220+)[26] identified 
using FITC­conjugated PNA and Alexa 700­conjugated 
anti­B220 mAb, CD4+ T cells were identified using 
PE­Cy7­conjugated anti­CD4 mAb and CD8+ T cells 
were identified using APC­conjugated anti­CD8β mAb. 
The following isotype controls were utilized: Alexa 
700-conjugated anti-rat IgG2aκ, PE-Cy7-conjugated 
anti­rat IgG2a+, APC­conjugated anti­rat IgG2b+ and 
PE­conjugated anti­rat IgG2a+ (eBioscience, San Diego, 
CA). PNA has no isotype control. Analysis was performed 
using a BD FACSCanto flow cytometer (BD, San Jose, 
CA) made available through the Flow Cytometry Core 
Facility at Iowa State University (Ames, IA). Data analysis 
was performed using FlowJo software (TreeStar Inc., 
Ashland, OR).
Western blot analysis
Sera from mdr1a­/­ and FVBWT mice were used to evaluate 
the presence of serum antibody against select members 
of the intestinal microbiota. Whole cell sonicates (WCS) 
of three members of the clostridial cluster group 
XIVa (ASF356, ASF500, and ASF502) were cultivated 
anaerobically, cells were harvested by centrifugation, 
washed in PBS, lyophilized, and stored at ­20 ℃ until 
use[27,28]. Cells were then weighed and suspended in PBS 
to 2 mg/mL. The resulting suspension was sonicated on 
ice for 3 min at the following settings: Amplitude of 50 for 
2, 30 s pulses with 5 s between each pulse; amplitude 
75 for 2, 30 s pulses with 5 s between each pulse; 
amplitude 100 for 2, 30 s pulses with 5 s between each 
pulse. The sonicate was sterilized by UV light (six­minute 
exposure) and sterility was confirmed bacteriologically. 
For each preparation, protein content was determined 
by bicinchoninic acid (BCA) analysis (Pierce Laboratories, 
New Haven, Connecticut, United States), aliquoted 
and stored at ­20 ℃. Whole cell sonicates of ASF356, 
ASF500, and ASF502 (8 µg of total protein content) 
were subjected to SDS­PAGE using 12% tris­glycine 
gels (BioRad, Hercules, CA) and transferred to PVDF 
membranes. Each individual antigen was analyzed using 
pooled anti­sera (1:250) from separate treatment groups 
as described above The membranes were then reacted 
with alkaline phosphatase (AP) conjugated anti­mouse 
IgG (H+L) (1:1000, Southern Biotech, Birmingham, 
AL) in a solution containing tris buffered saline (pH 7.6), 
1% Tween 20 (TBST) and 2.5% non­fat, skim milk. 
Immunoreactive proteins were visualized using Sigma 
fast red tablets (Sigma, St. Louis, MO) according to 
manufacturers’ instructions. 
Pathway finder R2 profiler PCR array analysis
To evaluate the activation of signal transduction 
pathways modulated by treatment with the P. vulgaris 
extract, cecal gene expression was analyzed using 
the RT2 profiler signal transduction pathway finder 
PCR array from QIAGEN (Germantown, MD) as per 
the manufacturer’s instructions. In brief, total RNA 
was isolated from cecal tissue collected that had been 
stored at ­20 ℃ in RNAlater using the TRIzol method[29]. 
RNA was further purified using the RT2 qPCR­grade 
RNA isolation kit from QIAGEN (Germantown, MD) 
according to manufacturer’s instructions. RNA quality 
(8.2 to 9.4) was assessed using an Agilent 2100 
BioAnalyzer (Agilent Technologies, Palo Alto, CA). Prior 
to preparation of cDNA, RNA samples were tested 
by PCR using oligonucleotide primers for GAPDH to 
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confirm the absence of genomic DNA contamination. 
Invitrogen SYBR Green/ROX, primers and 1 µg of 
isolated RNA from each mouse were subjected to the 
following PCR conditions and were run on an ABI 5700 
(Applied Biosystems Inc., Carlsbad, CA): 95 ℃ for 10 
min, followed by 40 cycles of amplification (95 ℃ for 
10 s, 60 ℃ for 15 s). All cycle threshold (CT) values 
were greater than 30, and were acceptable for further 
use (data not shown). GAPDH oligonucleotide primers 
used were: 5'­TGTGTCCGTCGTGGATCTGA­3' and 
5'­CCTGCTTCACCACCTTCTTGA­3'. RNA (1 µg) from each 
mouse was then converted to cDNA using QIAGEN RT2 
First Strand kit according to manufacturers’ instructions. 
Resulting cDNA from individual mice was pooled into 
diseased and healthy groups of mice for each treatment 
group and each experiment, mixed with the kit’s array 
master mix experimental cocktail preparation, and 
subjected to the same PCR conditions and equipment 
noted above. PCR array data was analyzed using 
QIAGEN RT2 PCR array analysis software and fold 
changes were calculated relative to house­keeping 
genes by the software. Only 2­fold changes or greater 
were considered.
Statistical analysis 
Following review by a biostatistician for appropriateness 
of the statistical methods used, all data, except survival 
curves, were evaluated by the Kruskal­Wallis test with 
Dunn’s multiple comparisons test. Because the Kruskal­
Wallis test has no analog of the ANOVA linear contrast 
that focuses attention on a specific pre­specified 
comparison of groups, differences in the mdr1a­/­ groups 
were further evaluated by the Mann­Whitney test for 
ordinal data and unpaired t­test with Welch’s correction 
for continuous data. Survival curves were evaluated by 
the Log­rank (Mantel­Cox) test. A P­value of < 0.05 was 
considered statistically significant. Prism 6 software was 
used for all statistical calculations. 
RESULTS
The ethanolic extract of P. vulgaris decreases severity 
of macroscopic disease parameters and delays onset of 
severe colitis in mdr1a-/- mice
To determine the efficacy of P. vulgaris extract in the 
treatment of spontaneous colitis, mdr1a­/­ and FVBWT 
mice were gavaged daily with vehicle (5% ethanol) or 
2.4 mg P. vulgaris extract. Previously published data 
shows that mdr1a­/­ mice develop disease between 8 
and 36 wk of age, with the average age of disease onset 
occurring at 20 wk[30]. As expected, FVBWT mice treated 
with P. vulgaris were not adversely affected by the 
administration of the extract despite the long course (14 
wk) of treatment (data not shown). As anticipated, many 
vehicle­treated mdr1a­/­ mice developed severe colitis 
and weight loss and were removed from study prior 
to 20 wk of age. Out of 16 mdr1a­/­ mice treated with 
vehicle, 7 required removal from study prior to 20 wk 
of age, compared to only 4 out of 13 P. vulgaris­treated 
mdr1a­/­ mice. Treatment with the P. vulgaris extract 
was able to delay onset of severe colitis and reduce 
the number of mdr1a­/­ mice that had to be removed 
from study, the difference was not significant when 
compared to vehicle­treated mdr1a­/­ mice (Figure 1). In 
addition, the phlogistic nature of the resident microbiota 
contributes to the mucosal inflammation in mdr1a­/­ mice 
as evidenced by the ability of metronidazole treatment 
to prevent the onset of clinical disease (Figure 1).
Representative photographs (Figure 2) show the 
extent of macroscopic and microscopic tissue damage in 
vehicle­treated mdr1a­/­ mice. In these mice, ceca were 
atrophied with visibly enlarged cecal tonsils suggesting 
immune activation. The ceca of the vehicle­treated 
mdr1a­/­ mice were almost devoid of contents, and both 
cecal and colonic tissues are notably thickened and rigid. 
Occasional blood was noted in cecal and colonic contents 
while no formed fecal pellets were noted in the vehicle­
treated mdr1a­/­ mice. Conversely, the ceca and colons 
of P. vulgaris­treated mdr1a­/­ mice were markedly 
improved and more closely resembled the tissue 
appearance of healthy FVBWT as well as metronidazole­
treated mdr1a­/­ mice with regard to all parameters 
assessed. 
Macroscopically, mild to severe typhlocolitis (a 
score of 2 to 9, respectively) was observed in 100% of 
vehicle­treated mdr1a­/­ mice while all of the P. vulgaris­
treated mice presented with macroscopic scores below 
the average score of the vehicle­treated mdr1a­/­ mice 
(Figure 2C). P. vulgaris prophylaxis significantly (P < 
0.05) improved macroscopic parameters of disease 
when compared to vehicle treatment in mdr1a­/­ mice. 
In addition, the median colon length for P. vulgaris-
treated mdr1a­/­ mice was longer than that for the 
vehicle­treated in mdr1a­/­ mice indicating less severe 
epithelial injury (Figure 2). Regardless of the treatment, 
FVBWT mice did not exhibit any signs of clinical disease 
or tissue damage (Figure 2). These results indicate 
that treatment with the P. vulgaris ethanolic extract 
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Figure 1  Effect of treatment with a Prunella vulgaris ethanolic extract on 
the onset of colitis in mdr1a-/- mice. Mdr1a-/- mice were removed from the 
study as they developed severe clinical disease (e.g., > 15% weight loss) before 
the termination of the experiment as described in Materials and Methods. aP < 
0.05, as compared to FVBWT control mice. Vehicle-treated mdr1a-/- mice n = 16, 
metronidazole-treated mdr1a-/- mice n = 10, Prunella vulgaris-treated mdr1a-/- 
mice n = 13. This survival (i.e., mice remaining on study) curve is representative 
of two independent experiments.
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attenuated macroscopic disease and delayed the onset 
of spontaneous colitis in mdr1a­/­ mice.
Impact of P. vulgaris treatment on the severity of 
histopathological lesions
Histological inflammation of the cecum (Table 1) and 
colon (data not shown) was evaluated in the context 
of mucosal height, ulceration, extent and character of 
inflammatory cell infiltrate, edema, stromal collapse 
and glandular necrosis, and glandular hyperplasia. The 
ceca of vehicle­treated mdr1a­/­ mice were characterized 
by crypt hyperplasia, extensive transmural ulceration 
and inflammatory cell infiltration, as well as submucosal 
edema and occasional stromal collapse (Figure 2 and 
Table 1). P. vulgaris­treated mdr1a­/­ mice exhibited 
statistically significant (P < 0.05) improvement in 
inflammation, edema, gland hyperplasia, and neutrophil 
infiltration (Table 1). As expected, FVBWT mice presented 
with no evidence of mucosal inflammation. While 100% 
of vehicle­treated mdr1a­/­ mice exhibited extensive 
neutrophilic infiltration into the cecal lamina propria, 
neutrophils were only noted in cecal mucosa of 38% of 
P. vulgaris­treated mdr1a­/­ mice (Figure 2 and Table 
1). As a measure of the infiltration of granulocytes 
Microscopic parameter FVBWT vehicle (n  = 6) mdr1a-/- vehicle (n  = 10) mdr1a-/- P. vulgaris (n  = 7)
Mucosal height (µm)  3.5 ± 0.2a   4.6 ± 0.2    3.9 ± 0.2
Ulceration 0.2 ± 0.2   1.9 ± 0.3    1.2 ± 0.4
Inflammation  1.3 ± 0.2b   3.6 ± 0.2     2.5 ± 0.4c
Edema  0.7 ± 0.5a   2.4 ± 0.3     0.9 ± 0.3c
Stromal collapse (necrosis)  0.0 ± 0.0a   1.7 ± 0.4    0.5 ± 0.4
Gland hyperplasia  1.2 ± 0.2b   2.8 ± 0.2     2.1 ± 0.3c
Additive cecal score  6.9 ± 0.9b 17.0 ± 1.2 11.1 ±1.5
Mice exhibiting cecal neutrophil infiltrate 17%b 100% 38%c
Table 1  Histopathological scores of cecal tissue
Average values are shown here ± standard error of the mean except where noted. aP < 0.05, bP < 0.01 compared to mdr1a-/- vehicle with 
Kruskal-Wallis test with Dunn’s multiple comparisons test. cP < 0.05 compared to mdr1a-/- vehicle with Mann-Whitney test.
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Figure 2  Oral administration of a Prunella vulgaris extract attenuated both microscopic and macroscopic cecal lesions in mdr1a-/- mice. A: Representative 
photographs of ceca and colons (left) and representative photomicrographs (200 ×) of histological sections of ceca (right) collected at necropsy from FVBWT or mdr1a-/- 
mice treated with either vehicle or Prunella vulgaris (P. vulgaris) extract; B: Colon lengths were measured at necropsy and the group range is represented. Whiskers 
indicate minimum and maximum values, while the horizontal line represents the group median; C: Macroscopic typhlocolitic scores were assigned at necropsy as 
described in the Materials and Methods (Max/Severe = 9, Min/Healthy = 0). aP < 0.05, bP < 0.01 compared to mdr1a-/- vehicle as calculated by Kruskal-Wallis test. 
Vehicle-treated FVBWT mice n = 6, vehicle-treated mdr1a-/- mice n = 16, P. vulgaris-treated mdr1a-/- mice n = 13.
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into the mucosal tissue, MPO activity was assessed in 
tissue homogenates. In comparison to tissue samples 
from vehicle­treated mdr1a­/­ mice, the associated 
MPO activity was significantly diminished in P. vulgaris­
treated mdr1a­/­ mice (P < 0.05) (Figure 3). In contrast 
to colon length, there was no histological evidence 
that the P. vulgaris treatment attenuated microscopic 
lesions when compared to vehicle­treated mdr1a­/­ 
mice (data not shown), suggesting that the bioactive 
benefit of P. vulgaris localized in the cecum. Together, 
these data indicated that the benefits provided by the 
oral administration of P. vulgaris were to attenuate the 
severity of inflammation and injury in the cecal mucosa 
in association with a reduction of the presence or 
recruitment of inflammatory granulocytes.
Impact of the ethanolic extract of P. vulgaris on the 
induction of innate chemotactic and pro-inflammatory 
cytokines 
To further investigate the mechanism(s) related to 
improved mucosal homeostasis and the associated 
reduction in neutrophils and MPO activity in the colons 
of P. vulgaris­treated mdr1a­/­ mice, serum samples 
collected at necropsy were examined for the presence of 
chemokines and cytokines. Of those present in the kit, 
multiple cytokines/chemokines (Eotaxin, IL­13, IL­15, IL­
1α, IL­1β, IL­2, IL­3, IL­4, IL­5, LIF, LIX, M­CSF, MCP­1, 
MIP­1α, MIP­2, and RANTES) were not detectable in 
the serum of any treatment group (data not shown). 
However, several analytes were significantly elevated 
in mdr1a­/­ mice compared to FVBWT mice including 
G­CSF, IL­10, CXCL10, KC, CXCL9, and TNF­α (P < 
0.01), and IL­9 (P < 0.05) (Table 2). When comparing 
P. vulgaris extract­treated to vehicle­treated mdr1a­/­ 
mice, the levels of IL­10 (P < 0.01) and CXCL9 (P < 
0.05) and TNF­α (P < 0.05) were significantly lower in 
the P. vulgaris­treated mdr1a­/­ mice (Table 2). For the 
remainder of the cytokines/chemokines listed in Table 
2, there was a trend for lower amounts in the serum 
of P. vulgaris­treated mdr1a­/­ mice when compared 
to vehicle­treated mdr1a­/­ mice. This data indicates 
that oral administration of the ethanolic extract of P. 
vulgaris is able to attenuate production of several innate 
chemokines and cytokines induced by the inflammatory 
response in mdr1a­/­ mice. 
Differential regulation of gene expression pathways by 
in vivo treatment with the ethanolic extract of P. vulgaris
To further characterize the attenuation of mucosal 
inflammation provided by P. vulgaris treatment, a 
microarray analysis for inflammatory gene expression 
was performed in order to identify differential gene 
regulation between disease phenotypes of botanical 
extract­treated mdr1a­/­ mice (e.g., healthy = macro­
scopic score < 2 ; colitic = macroscopic score ≥ 2) and 
between FVBWT mice and mdr1a­/­ mice treated with 
vehicle. At the extremes of microscopic and macroscopic 
lesion scores, it was observed that no vehicle treated 
mdr1a­/­ mice were characterized as “healthy” and no 
FVBWT mice were characterized as “colitic” (data not 
shown). Genes encoding CCL2, CXCL1, CXCL9, IL-
1α, MMP10, TNF-α, VCAM-1, CCL20, and IL-2 were all 
downregulated more than 2­fold by P. vulgaris treatment 
in mdr1a­/­ mice that did not develop colitis (Table 3). 
P. vulgaris treatment appears to modulate the NF­κB 
pathway in the preservation of mucosal homeostasis in 
mdr1a­/­ mice. 
Influence of P. vulgaris on local T cell and B cell 
populations
Because T and B cells are activated as a consequence 
of inflammation, T cell and B cell populations in the 
cecal tonsils of mdr1a­/­ and FVBWT mice were analyzed 
to evaluate the effects of P. vulgaris treatment on local 
lymphocyte populations (Figure 4). Severe colitis in 
vehicle­treated mdr1a­/­ mice resulted in 3­fold more 
CD4+ T cells (Figure 4A) and 6­fold more CD8+ T cells 
(Figure 4B) in the cecal tonsil as compared to vehicle 
gavaged FVBWT mice. In P. vulgaris-treated mdr1a­/­ 
mice, the numbers of CD4+ T cells in the cecal tonsils 
were significantly lower (P < 0.05) when compared to 
vehicle­treated mdr1a­/­ mice (Figure 4A), and there was 
a trend indicating fewer CD8+ T cells in the P. vulgaris-
treated mdr1a­/­ mice (Figure 4B). 
Vehicle­treated mdr1a­/­ mice exhibited a 2.5­fold 
increase in the number of PNA+B220+ germinal center 
B cells (Figure 4C) in the cecal tonsil as compared to 
vehicle gavaged FVBWT mice. Remarkably, P. vulgaris 
treatment significantly (P < 0.05) decreased PNA+B220+ 
germinal center B cells in mdr1a­/­ mice (Figure 4C). 
Together, these data indicate that the expansion CD4+ T 
cell and PNA+B220+ germinal center B cell populations 
were significantly lower in the cecal tonsils of P. vulgaris­
treated mdr1a­/­ mice. 
P. vulgaris prevents antigenic responses to some 
members of the intestinal microbiota 
Antibody responses to antigens derived from the gut 
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Figure 3  Administration of a Prunella vulgaris ethanolic extract reduced 
local myeloperoxidase activity in the colon of mdr1a-/- mice. Homogenates 
of colonic tissue were subjected to an assay for MPO activity. aP < 0.05, bP < 
0.01 compared to mdr1a-/- vehicle as calculated by Kruskal-Wallis test. Vehicle-
treated FVBWT mice n = 6, vehicle-treated mdr1a-/- mice n = 10, P. vulgaris-
treated mdr1a-/- mice n = 7. MPO: Myeloperoxidase; P. vulgaris: Prunella 
vulgaris.
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microbiota (e.g., clostridial cluster group XIVa) have 
been noted in IBD patients and in murine models of 
IBD[31­33]. These antibody responses are indicative of a 
loss of epithelial integrity and immune tolerance to the 
microbiota and do not occur in healthy humans or mice. 
Pooled serum samples from mdr1a­/­ mice treated with P. 
vulgaris were evaluated by immunoblot analysis against 
antigens (i.e., whole cell sonicate) derived from select 
members of the clostridial cluster group XIVa within the 
microbiota (Figure 5). As anticipated, sera from FVBWT 
mice did not display antibody reactivity against these 
bacterial antigens, suggesting that these mice maintained 
immunological tolerance to their gut microbiota. 
Conversely, sera from vehicle­treated mdr1a­/­ mice did 
contain antibodies reactive to these bacterial antigens, 
indicating a loss of immunologic tolerance to these mem­
bers of the microbiota. Sera from P. vulgaris­treated 
mdr1a­/­ mice displayed little to no detectible antibody 
response to the three bacterial antigens (Figure 5).
DISCUSSION
As the long term safety and efficacy of current parenteral 
therapeutics for IBD are a concern and antibiotics are 
deemed unreliable for long­term use in IBD patients, 
there is a need for new therapies that may include 
complementary treatments[8,9,34]. Complementary 
and alternative therapy including nutraceuticals hold 
realistic potential in treating or supplementing treatment 
of inflammatory disorders, as the anti­inflammatory 
and antioxidant benefits of plant­derived components 
are becoming more extensively characterized[35­39]. 
P. vulgaris, already popular in Asian medicine, is a 
viable candidate for study as a therapeutic agent in the 
treatment of IBD as it contains several anti-inflammatory, 
immunomodulatory, and antioxidant flavonoids, poly­
phenols, and triterpenoids and has no documented toxic 
side­effects[37,40­44]. In this regard, rosmarinic acid, the 
most plentiful phenolic compound found in P. vulgaris, 
was found to protect mice against the deleterious effects 
associated with sepsis by downregulating inflammatory 
genes in the NF­κB pathway including the related pro­
inflammatory cytokines TNF-α and IL­6[45]. 
The mdr1a­/­ mouse model is ideal to use for studies 
of potential IBD therapeutics that are relevant to human 
medicine as mdr1a­/­ mice are immunocompetent, 
develop spontaneous colitis in the context of a leaky 
intestinal epithelium, and exhibit cytokine profiles and 
Cytokine/chemokine FVBWT vehicle (n  = 6) mdr1a-/- vehicle (n = 16) mdr1a-/-  P. vulgaris  (n  = 13)
G-CSF 140.1 ± 15b   9694.0 ± 2563   4597.0 ± 1931
GM-CSF ND   21.1 ± 11   1.5 ± 1
IL-9   77.9 ± 27a 200.1 ± 38 117.8 ± 14
IL-10 NDb 19.4 ± 4      4.6 ± 2a,d
IL-17     4 ± 2    16 ± 4      1 ± 1
CXCL10   8.4 ± 5b   724.3 ± 136 397.2 ± 85
KC   69.5 ± 24b   527.1 ± 119 253.4 ± 58
CXCL9 108.7 ± 37b 3901.0 ± 858  1319.0 ± 277c
TNFα      9.3 ± 0.1b 14.8 ± 1    9.9 ± 3c
Table 2  Assessment of selected cytokines in the serum of mice
Serum samples were collected at the time mice were euthanized and analyzed as described in Materials and 
Methods. Average values (pg/mL serum) are shown here ± standard error of the mean except where noted. aP < 
0.05, bP < 0.01 compared to mdr1a-/- vehicle with Kruskal-Wallis test with Dunn’s multiple comparisons test. cP < 
0.05, dP < 0.01 compared to mdr1a-/- vehicle with unpaired t-test with Welch’s correction. ND: Not detectable; P. 
vulgaris: Prunella vulgaris.
Fold change compared to vehicle-treated mdr1a-/- micea
Gene Pathway affiliation FVBWT vehicle healthy mdr1a-/- P. vulgaris  healthy mdr1a-/- P. vulgaris  colitic
Ccl2 NF-κB, LDL   -7.3 -3.4 -1.1
Cxcl1 NF-κB -11.3 -7.2 -1.0
Cxcl9 NF-κB, Jak/Stat -23.9 -4.2 -1.1
Icam1 NF-κB, Phospholipase C   -3.2  -1.2  1.8
Il1a NF-κB -13.4 -8.0  1.3
Mmp10 NF-κB, Jak/Stat   -6.6 -8.5  1.2
TNFα NF-κB -10.2 -2.6  1.2
Vcam1 NF-κB, Phospholipase C, LDL   -3.8 -2.0  1.2
Ccl20 NF-κB   -3.6 -2.0  1.4
Il2 NF-κB, NFAT, Calcium, PKC   -3.7 -2.2 -1.5
Table 3  Attenuation of inflammatory gene expression in mdr1a-/- mice treated orally with an extract from 
Prunella vulgaris
aA negative value indicates that there was a lower level of gene expression when compared to the level of gene expression in 
vehicle-treated mdr1a-/- mice that developed severe colitis. P. vulgaris: Prunella vulgaris.
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immune responses similar to those documented in 
clinical IBD cases[30,46­51]. It was previously demonstrated 
that administration of curcumin attenuated mucosal 
inflammation in mdr1a­/­ mice[52]. In these studies, 
similar to previously published studies, onset of clinical 
disease (e.g., weight loss) in vehicle­treated mdr1a­/­ 
mice was observed at roughly 10 wk of age (Figure 
1)[30]. In contrast, onset of clinical disease was delayed 
by treatment with the P. vulgaris extract; in addition, 
markedly fewer of the mdr1a­/­ mice treated developed 
severe clinical disease by 20 wk of age (Figure 1). P. 
vulgaris treatment of mdr1a­/­ mice was also found 
to attenuate macroscopic lesions associated with the 
characteristic severe typhlocolitis observed in this 
murine model (Figure 2). In contrast to the vehicle­
treated mdr1a­/­ mice, ceca of mdr1a­/­ mice treated 
with a P. vulgaris extract retained normal mucosal 
architecture, lacked enlarged lymphoid aggregates, and 
retained luminal contents devoid of blood or mucus. 
Macroscopically, the colons of botanical­treated mdr1a­/­ 
mice were more similar in appearance to the colons 
of the FVBWT control mice with regard to presence of 
formed feces, and lack of grossly visible tissue edema 
and rigidity (Figure 2). Mdr1a­/­ mice treated with P. 
vulgaris extract also presented with normal colon lengths 
(Figure 2); microscopically, colonic lesions were less 
attenuated in the botanical extract­treated mdr1a­/­ mice 
than those present in the cecum (data not shown). The 
microscopic lesions observed in the ceca of mdr1a­/­ mice 
treated with P. vulgaris were markedly less severe when 
compared to those observed for vehicle­treated mdr1a­/­ 
mice (Table 1). Together, these findings highlight the 
differences between colonic and cecal compartments in 
terms of the magnitude of the disease. Perhaps these 
differences arise from the more dense concentration 
of metabolically active microbes in the cecum as 
compared to the colon, which may lead to more efficient 
metabolism/degradation of the extract and greater 
health benefit at more proximal gastrointestinal sites. 
Although the etiology of IBD is still ill defined, many 
recognize that the inductive phase of colitis involves 
a compromised intestinal epithelium and activation 
of innate immune responses, including neutrophil 
activation, transmigration across the mucosal epithelium, 
and enzymatic damage to host tissues[3,53­56]. Flavonoids 
from licorice have been shown to inhibit neutrophil 
infiltration into lung tissue after lipopolysaccharide­
induced inflammation and reduce the severity of 
associated inflammatory damage to host pulmonary 
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Figure 4  Evaluation of T cell and B cell subsets in the cecal tonsil of 
mdr1a-/- mice treated with prunella vulgaris ethanolic extract. Cecal tonsils 
were excised at necropsy, single cell suspensions prepared and labeled for flow 
cytometric analysis as described in Materials and Methods. Absolute numbers 
of (A) CD4+ T cells; (B) CD8ß+ T cells; and (C) B220+PNA+ germinal center 
B cells in the cecal tonsils of mice. aP < 0.05, bP < 0.01 compared to mdr1a-/- 
vehicle as calculated by Kruskal-Wallis test. cP < 0.05 compared to mdr1a-/- 
vehicle as calculated by unpaired t-test. The n for each group is equal to that 
noted in Figure 1 and data are representative of two independent experiments. 
Vehicle-treated FVBWT mice n = 5-6, vehicle-treated mdr1a-/- mice n = 8-10, P. 
vulgaris-treated mdr1a-/- mice n = 5-7.
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Figure 5  Vehicle-treated mdr1a-/- mice with severe colitic inflammation 
developed serum antibody to antigens derived from gut microbiota while 
those treated with prunella vulgaris extract do not. Whole cell sonicates of 
three separate clostridial species present as part of the intestinal microbiota 
(altered Schaedler flora members 356, 500 and 502) were subjected to SDS-
PAGE. Western blot analysis was performed using sera collected at necropsy. 
Antigens in lanes represented in each panel are as follows from left to right: 
ASF502, ASF500 and ASF356.
 Haarberg KMK et al . Prunella vulgaris  attenuates colitis
233 November 6, 2015|Volume 6|Issue 4|WJGPT|www.wjgnet.com
tissues[57]. As a group, the mdr1a­/­ mice treated with the 
P. vulgaris ethanolic extract presented with markedly 
less neutrophilic infiltration into the cecal mucosa when 
compared to vehicle­treated mdr1a­/­ mice (Table 1). 
Reduction of the neutrophilic infiltrate in these mice 
was correlated with less severe microscopic scores and 
a significant decrease in tissue levels of MPO activity 
(Figures 2 and 3, Table 1). MPO enzymatic activity is a 
known correlate to intestinal damage and is often used 
as a marker of IBD severity in many animal models of 
colitis[58­62]. 
Since neutrophils are not resident in tissues, cytokine 
and chemokine signals produced by epithelial cells and 
local macrophages are responsible for the recruitment of 
neutrophils into the mucosal tissues[63,64]. Homeostatic 
production of these innate chemokines is central to 
mucosal health, while over­production contributes to 
the development of severe inflammation in colitis[55,56,65]. 
Debate regarding the role of NF­κB activation and 
the exacerbated recruitment innate immune cells 
in acute intestinal inflammatory models continues, 
with some research pointing to a protective effect by 
these components and others revealing a deleterious 
effect[23,66­68]. However, many agree that dysregulation 
of NF­κB signaling and the consequent innate cellular 
responses are causative factors in the inductive phase 
and maintenance of chronic inflammation associated 
with human CD and UC[69­71]. Pro­inflammatory 
mediators induced by activation of NF­κB are abnormally 
upregulated in CD and UC patients[72]. Moreover, it 
concludes nuclear translocation of NF­κB in epithelial 
cells and local monocytes upregulates production of 
pro­inflammatory cytokines and chemokines such as 
TNF­α, IL­1β, KC, and CXCL9. These cytokines increase 
expression of adhesion molecules (i.e., VCAMs, ICAMs, 
and MadCAM ) on endothelial cells, while chemokines 
create chemical gradients to attract neutrophils and 
other innate inflammatory cells to sites of injury[55,64,65,73]. 
Others have reported that the ability to regulate or 
attenuate cytokine production (e.g., TNF­α, IL­1α, IL­
1β, IFN­γ) decreases the expression of chemokines 
(e.g., IL­8/KC and VEGF) and adhesion molecules on 
endothelial cells resulting in amelioration of inflammatory 
tissue damage in several disease models, including 
colitis[1,45,66,74]. The patterns of cytokine and chemokine 
production observed in aged­matched, vehicle­treated 
mdr1a­/­ mice in the current study (Table 2) was 
consistent with that previously reported[51]. Serum 
samples from mdr1a­/­ mice treated with the ethanolic 
extract of P. vulgaris had lower levels of cytokines that 
would contribute to the production of granulocytes 
and monocytes (G­CSF and GM­CSF) as well as the 
neutrophil chemotactic factor KC (Table 2). Importantly, 
treatment with the P. vulgaris extract reduced serum 
levels of TNF­α (Table 2), a cytokine known to be a 
key regulator of inflammatory responses in colitis[75]. 
These data indicate that P. vulgaris extract reduced the 
production of cytokines and chemokines central to the 
induction and maintenance of chronic inflammation. 
Activation of the transcription factor NF­κB and the 
regulation of its target genes have well documented 
links to the chronicity of inflammation associated with 
IBD[29,69­71]. Recent studies have shown that flavonoids 
similar to those identified in P. vulgaris are capable 
of downregulating NF­κB and ultimately regulating 
the production of innate chemotactic factors and pro­
inflammatory cytokines[76,77]. One such study showed 
that the flavonoid luteolin decreased NF­κB expression 
in the ceca and colons of IL­10­/­ mice, and effectively 
ameliorated spontaneous colitis[23]. Similarly, the 
ethanolic extract of P. vulgaris, which is known to contain 
several flavonoids (data not shown)[15], downregulated 
expression of chemokine genes (Ccl2, Cxcl1/KC, 
Cxcl9/CXCL9, and Ccl20) and genes involved in the 
increased expression of adhesion molecules (VCAM-1, 
ICAM, TNFα and IL-1α) and tissue remodeling to allow 
for inflammatory cell transmigration (MMP-10) (Table. 
3). All of these genes participate in the activation of or 
are regulated by NF­κB[78­83]. Based on our findings, 
the ethanolic extract of P. vulgaris likely attenuates 
neutrophil recruitment into the colonic tissues of mdr1a­/­ 
mice by downregulating genes regulated by NF­κB 
signaling. The importance of regulating inflammation 
in mdr1a­/­ mice prior to the onset of clinical disease is 
underscored by recent data showing that regulation 
of inflammatory gene expression is altered in mdr1a­/­ 
mice and in mice treated with dextran sodium sulfate 
(DSS) prior to any histologic signs of inflammation[84,85]. 
Since defects in gene expression precede inflammation, 
prophylactic approaches to control mucosal inflammation 
rather than providing therapy at or after the onset of 
an inflammatory flare may prove advantageous. In 
the current study, therapeutic initiation of P. vulgaris 
treatment (i.e., after colitic onset) was ineffective at 
reducing the severity of inflammation (data not shown). 
This observation supports the current hypothesis that 
the ethanolic extract of P. vulgaris modulates innate 
inflammatory gene expression, and that effective 
treatment should begin prior to the onset of clinical 
disease. 
In addition to NF­κB signaling and innate immune 
activation, adaptive immune responses also play an 
integral role in mediating the chronicity and severity of 
colitic disease in experimental models and in humans 
with IBD. In particular, aberrant CD4+ T cell responses to 
antigens derived from the resident microbiota have been 
implicated in the pathogenesis of IBD[31,86]. Pretreatment 
with the ethanolic extract of P. vulgaris decreased 
production of CXCL10 and CXCL9, two proteins that 
are induced by IFN­γ and are chemotactic for T cells 
(Table 2)[79,87]. These chemokines and other cytokines 
participate in inflammatory feedback loops that may 
be interrupted by treatment with the ethanolic extract 
of P. vulgaris. The observation of reduced numbers of 
CD4+ and CD8+ T cells in the cecal tonsils of mdr1a­/­ 
mice (Figure 4) is consistent with the lower amounts of 
CXCL10 and CXCL9 in the serum. There were also lower 
levels of IL­9 in the serum of mdr1a­/­ mice treated with 
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the ethanolic extract of P. vulgaris (Table 2), a cytokine 
known to enhance CD4+ T cell proliferation and inhibit 
apoptosis[88]. Moreover, the decreased expression of 
CXCL9, Ccl2, IL-1α, TNF-α, and Ccl20 genes in extract 
treated mdr1a­/­ mice provides additional evidence 
that treatment with P. vulgaris extract impacted the 
robustness of the local T cell response (Table 3). CCL20 
is strongly chemotactic for immature dendritic cells, 
which would mature upon collecting antigen in the 
tissues, present that antigen to T cells, and stimulate an 
adaptive immune response[89].
With respect to the induction of antibody specific to 
antigens derived from the resident microbiota, germinal 
centers will develop in lymphoid tissue upon B cell 
activation by T dependent antigens[90]. The results of this 
study demonstrated that the number of PNA+B220+ B 
cells present in P. vulgaris-treated mice was significantly 
less than that detected in the vehicle­treated mdr1a­/­ 
mice (Figure 4). As a consequence of the attenuated 
germinal center B cell response, there was a lack of 
antibody production towards bacterial antigens derived 
from the resident microbiota in P. vulgaris­treated 
mdr1a­/­ mice (Figure 5). Collectively, these data present 
evidence that the ethanolic extract of P. vulgaris acts 
to maintain mucosal homeostasis in mdr1a­/­ mice 
by regulating gene expression associated with innate 
inflammatory responses and attenuating the activation 
of the adaptive immune response.
It has been recently reported that 40% to 50% 
of adults suffering with inflammatory bowel disease 
or irritable bowel disease utilize complementary and 
alternative medicine to treat their symptoms[34]. Because 
of the prevalence at which patients use complementary 
approaches to attenuate clinical symptoms, it is critical 
to evaluate the efficacy of nutraceuticals in pre­clinical 
controlled studies. The work highlighted in this study 
indicates that an ethanolic extract derived from P. 
vulgaris was safe when administered daily for 14 wk and 
markedly attenuated the severity of colitis in mice that 
are genetically prone to develop mucosal inflammation. 
The health benefits associated with consuming plant­
derived nutraceuticals are likely associated with the 
richness and complexity of anti-inflammatory compounds 
present in botanical extracts. There is a need to further 
evaluate the underlying mechanism(s) that contributed 
to the anti-inflammatory activity of P. vulgaris extracts 
in order to provide a basis for their legitimate use as a 
prophylactic or supplementary option for the treatment 
of IBD and other chronic inflammatory disorders. 
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Background
Extracts of Prunella vulgaris (P. vulgaris) have been shown to contain anti-
inflammatory components but there is limited information regarding the ability 
of these extracts to attenuate or prevent inflammation in vivo. Mice that are 
deficient in the expression of the multiple drug resistance gene (i.e., mdr1a-/-) 
develop spontaneous colitis by 12 to 15 wk of age. As opposed to chemically-
induced models of colitis, these mice offer a excellent model to assess the 
anti-inflammatory capabilities of botanical extracts administered as an oral 
formulation.
Research frontiers
Treatment of inflammatory bowel disease is dominated by the use of drugs and 
biologicals that systemically target inflammatory processes. The development 
of effective treatment modalities that can be delivered orally and target the 
inflammatory response in the gastrointestinal mucosa would reduce the 
systemic side-effects observed with other treatment regimen. The studies 
presented herein demonstrate that botanical extracts can effectively attenuate 
the severity of colitis on a murine model of spontaneous colitis.
Innovations and breakthroughs
This is the first study to demonstrate the oral administration of an ethanolic 
extract derived from P. vulgaris can be used to delay the onset of and 
ameliorate the severity of spontaneously occurring colitis in mdr1a-deficient 
mice. 
Applications
It is estimated that 30% to 70% of patients suffering from inflammatory bowel 
diseases use some form of complementary and alternative therapy to treat their 
symptoms. Many of the parenteral therapies (e.g., steroids, 5-aminosalicylates, 
monoclonal antibodies) used to control gastrointestinal inflammation are 
associated side-effects. The development of extracts derived from medicinal 
plants, such as P. vulgaris, that can be delivered orally and ameliorate 
gastrointestinal inflammation may be useful adjunct treatments for IBD patients.
Terminology
Mice lacking the multiple drug resistance (mdr1a) gene fail to produce an 
epithelial cell transporter protein (a 107 kDa P-glycoprotein) responsible for 
pumping various compounds across the cell membrane. The pathological 
lesions and cytokine profiles observed in the colon of mdr1a-deficient mice 
resembles that noted in human ulcerative colitis patients.
Peer-review
This is a well written manuscript, investigating the ability of an orally-
supplemented P. vulgaris extract to attenuate the clinical symptoms of colitis in 
an animal model of spontaneous colitis (mdr1a-/- mice). The authors used valid 
methodological approaches to compare the histopathological, biochemical and 
immunological profile of the supplemented and control animals, the presentation 
of the results was clear and the discussion was thorough.
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